Literature DB >> 15126778

Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma.

Ryuichiro Konda1, Hiroshi Sato, Fumihiko Hatafuku, Tatsuru Nozawa, Naomasa Ioritani, Tomoaki Fujioka.   

Abstract

PURPOSE: The development of renal cell carcinoma (RCC) is a critical problem in acquired renal cystic disease (ARCD) in patients with end stage renal disease, particularly males on chronic hemodialysis. We examined the expression of hepatcyte growth factor (HGF) and its receptor c-met in ARCD associated with RCC to elucidate the role of the HGF/c-met pathway in renal cyst development and subsequent tumor transformation.
MATERIALS AND METHODS: Immunohistochemical expression of HGF, c-met and Bcl-2 was examined in 15 normal tissue samples of kidneys obtained from nephrectomy for localized RCC and 19 with ARCD associated with RCC from 16 patients on dialysis. The expression of HGF mRNA was examined by reverse transcriptase-polymerase chain reaction.
RESULTS: In normal kidneys immunostaining for HGF was scarcely detected in renal tubular cells. Bcl-2 and c-met immunostaining was observed mainly in distal tubular cells. In nontumor areas of kidneys with ARCD associated RCC the expression of HGF and c-met was up-regulated in tubular and the cyst epithelial cells. Hyperplastic cysts with multilayer epithelium and micropapillary projection were the predominant cysts stained with HGF and c-met. Immunostaining for HGF and c-met was also detected in RCC regions. The Bcl-2 immunostaining pattern was similar to that of HGF and c-met in nontumor and RCC regions. On reverse transcriptase-polymerase chain reaction HGF mRNA expression was up-regulated in nontumor areas and RCC regions in ARCD.
CONCLUSIONS: These results suggest that up-regulation of HGF and its receptor c-met may be involved in renal cyst formation and subsequent tumor transformation in patients with end stage renal disease. Increased Bcl-2 expression may promote this process through the inhibition of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126778     DOI: 10.1097/01.ju.0000124263.51906.b9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

Review 1.  Acquired cystic kidney disease: an under-recognized condition in children with end-stage renal disease.

Authors:  Eugene Y H Chan; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2017-04-25       Impact factor: 3.714

2.  Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population.

Authors:  Alberto Breda; Giuseppe Lucarelli; Giuseppe Luccarelli; Oscar Rodriguez-Faba; Luis Guirado; Carmen Facundo; Carlo Bettocchi; Loreto Gesualdo; Giuseppe Castellano; Giuseppe Grandaliano; Michele Battaglia; Juan Palou; Pasquale Ditonno; Humberto Villavicencio
Journal:  World J Urol       Date:  2014-02-07       Impact factor: 4.226

3.  Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults.

Authors:  Aleksandar Denic; Mariam P Alexander; Vidhu Kaushik; Lilach O Lerman; John C Lieske; Mark D Stegall; Joseph J Larson; Walter K Kremers; Terri J Vrtiska; Harini A Chakkera; Emilio D Poggio; Andrew D Rule
Journal:  Am J Kidney Dis       Date:  2016-02-06       Impact factor: 8.860

4.  Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.

Authors:  Shan Qin; Mary Taglienti; Surya M Nauli; Leah Contrino; Ayumi Takakura; Jing Zhou; Jordan A Kreidberg
Journal:  J Clin Invest       Date:  2010-09-13       Impact factor: 14.808

Review 5.  The renal effects of ALK inhibitors.

Authors:  Hassan Izzedine; Rania Kheder El-Fekih; Mark A Perazella
Journal:  Invest New Drugs       Date:  2016-07-29       Impact factor: 3.850

6.  Acquired cystic disease-associated renal cell carcinoma: further characterization of the morphologic and immunopathologic features.

Authors:  Soomin Ahn; Ghee Young Kwon; Yong Mee Cho; Sun-Young Jun; Chan Choi; Hyun-Jung Kim; Yong Wook Park; Weon Seo Park; Jung Won Shim
Journal:  Med Mol Morphol       Date:  2013-03-08       Impact factor: 2.309

7.  Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology.

Authors:  Shuta Ishibe; Anil Karihaloo; Hong Ma; Junhui Zhang; Arnaud Marlier; Mitchihiro Mitobe; Akashi Togawa; Roland Schmitt; Jan Czyczk; Michael Kashgarian; David S Geller; Snorri S Thorgeirsson; Lloyd G Cantley
Journal:  Development       Date:  2009-01       Impact factor: 6.868

8.  High risk of development of renal cell tumor in end-stage kidney disease: the role of microenvironment.

Authors:  Anetta Nagy; Eva Walter; Dmitry Zubakov; Gyula Kovacs
Journal:  Tumour Biol       Date:  2016-01-20

9.  Complex renal cysts associated with crizotinib treatment.

Authors:  Patrick Schnell; Cynthia H Bartlett; Benjamin J Solomon; Vanessa Tassell; Alice T Shaw; Tommaso de Pas; Soo-Hyun Lee; Geon Kook Lee; Kaoru Tanaka; Weiwei Tan; Yiyun Tang; Keith D Wilner; Allan Safferman; Ji-Youn Han
Journal:  Cancer Med       Date:  2015-03-10       Impact factor: 4.452

Review 10.  Oncogenic mechanisms in renal insufficiency.

Authors:  Simona Ruxandra Volovat; Constantin Volovat; Ingrith Miron; Mehmet Kanbay; David Goldsmith; Cristian Lungulescu; Silvia Corina Badarau; Adrian Covic
Journal:  Clin Kidney J       Date:  2020-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.